Close gaps in culture-based testing before they delay product release

  • <<
  • >>

BlueskyReddit

Culture-based mycoplasma methods can extend timelines and may not detect every relevant organism fast enough for today’s cell therapy workflows. This application note reviews data from a qPCR-based MycoSEQ Plus workflow that delivered same-day results and detected all species evaluated in the study, including organisms not detected by the indicator cell culture arm of USP <63>. It also explores how rapid sterility testing can support earlier contamination checks across manufacturing.

Access Now

    Please fill out the information below to access the selected content. If you are already registered, and this information will be filled out for you.
  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • By submitting this form, you consent to Cell & Gene Therapy Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.